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Department, Moscow State University, Moscow, RussiaABSTRACT Injury-induced bleeding is stopped by a hemostatic plug formation that is controlled by a complex nonlinear and
spatially heterogeneous biochemical network of proteolytic enzymes called blood coagulation. We studied spatial dynamics of
thrombin, the central enzyme of this network, by developing a fluorogenic substrate-based method for time- and space-resolved
imaging of thrombin enzymatic activity. Clotting stimulation by immobilized tissue factor induced localized thrombin activity
impulse that propagated in space and possessed all characteristic traits of a traveling excitation wave: constant spatial velocity,
constant amplitude, and insensitivity to the initial stimulation once it exceeded activation threshold. The parameters of this trav-
eling wave were controlled by the availability of phospholipids or platelets, and the wave did not form in plasmas from hemophilia
A or C patients who lack factors VIII and XI, which are mediators of the two principal positive feedbacks of coagulation. Stim-
ulation of the negative feedback of the protein C pathway with thrombomodulin produced nonstationary patterns of wave forma-
tion followed by deceleration and annihilation. This indicates that blood can function as an excitable medium that conducts
traveling waves of coagulation.INTRODUCTIONBlood coagulation is a space- and time-dependent process of
plasma jellification that leads to formation of a plug prevent-
ing blood loss upon vascular injury. It is an intricate network
of serine proteases, cofactors, and inhibitors, which are ar-
ranged into a proteolytic cascade with at least six positive
and negative feedback loops. The presence of nonlinear
positive feedbacks in this spatially heterogeneous reaction-
diffusion system led to a prediction (1,2) that it can function
as an excitable medium—a spatially distributed, dissipative,
nonlinear system, in which complex spatiotemporal
phenomena such as traveling waves or Turing structures
can be observed. Excitable media play prominent roles in
chemistry, physics, engineering, and human sciences; two
classic examples in biology include neural impulse propaga-
tion (3) and morphogenesis (4).
Although the importance of positive and negative feed-
back loops in the spatial propagation of coagulation has
been confirmed by experiments and theoretical analyses
(5–7), the hypothetical traveling wave of thrombin has not
been directly observed. Fibrinogen, the primary substrate
for thrombin, is quickly depleted before the maximal
thrombin concentration is reached. Indeed, plasma becomes
fully clotted when only 5% of the total thrombin is gener-
ated. Although the clot density may be slightly predictive
of thrombin activity in a 200-mm zone near thrombogenic
cell monolayers (8), it has not been possible to reconstructSubmitted June 6, 2012, and accepted for publication October 1, 2012.
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0006-3495/12/11/2233/8 $2.00the spatiotemporal thrombin distribution inside the growing
clot, nor to predict the shape of possible traveling thrombin
waves.
In this study, we designed a fluorogenic substrate-based
four-dimensional-biochemistry approach to measure distri-
bution of thrombin as a function of space and time. Using
this strategy, we demonstrated formation of excitation waves
in blood plasma and identified the responsible mechanism.MATERIALS AND METHODS
Materials
Reagents were obtained from the following sources: 7-amino-4-methyl-
coumarin (Sigma-Aldrich, St. Louis, MO); Z-Gly-Gly-Arg-AMC (Bachem,
Torrance, CA); rabbit thromboplastin, factor VIII assay (Renam, Moscow,
Russia); brain phosphatidylserine and egg phosphatidylcholine (Avanti
Polar Lipids, Alabaster, AL); low melting point agarose (Fluka Chemie
AG, Buchs, Switzerland); corn trypsin inhibitor (Gamma, Pushchino,
Russia); factor VIII (Hemophil M, Baxter Russia, Moscow, Russia); factor
XI and rabbit lung thrombomodulin (Haematologic Technologies, Essex
Junction, VT); Actichrome TF test (American Diagnostica, Stamford,
CT); factor VIII-deficient plasma (George King Biomedical, Overland
Park, KS); and factor XI-deficient plasma (HRF, Raleigh, NC). The glyco-
protein IIb-IIIa antagonist Monafram was a generous gift of Prof. A. V. Ma-
zurov (Russian Cardiology Research and Production Center, Moscow,
Russia).Experimental setup
Experiments were performed with a specially designed videomicroscopy
system (Fig. 1 A) that allows for the simultaneous observation of spatial
fibrin clot propagation and thrombin generation. The plasma sample was
placed in the experimental chamber, and clotting was activated by bringinghttp://dx.doi.org/10.1016/j.bpj.2012.10.011
FIGURE 1 Spatiotemporally resolved imaging
of thrombin activity in blood plasma from a healthy
individual reveals a propagating wave. (A) Overall
experimental design: A layer of immobilized tissue
factor (1) induces fibrin clot propagation (2) in
nonstirred plasma (3). The sample is illuminated
in turn by red (4) or UV LEDs (5) through an exci-
tation filter (6). Light scattered by fibrin (7) and
fluorescence of the thrombin-generated AMC (8)
pass through a multiband emission filter (9) and
macro lens (10) and are recorded by a charge-
coupled device (11). (B) Fluorogenic substrate
Z-Gly-Gly-Arg-AMC is cleaved by thrombin to
yield fluorescent AMC. (C) Time-lapse images:
Light scattering from the growing fibrin clot (red)
or AMC fluorescence (blue). (D) AMC concentra-
tion distribution obtained from fluorescence (C).
(E) Fibrin concentration distribution obtained
from light scattering (C). (F) Thrombin distribu-
tion as a function of space and time obtained
from the AMC distribution (E) by solving a reverse
reaction-diffusion problem. Plasma is supple-
mented with 10 mM phospholipids; activation is
with 90 pmol TF/m2.
2234 Dashkevich et al.an activator with a tissue factor (TF)-coated surface in contact with plasma.
The chamber was maintained at 37C and illuminated with red (625 nm) or
ultraviolet (UV) (365 nm) LEDs (Optotech, Hsinchu, Taiwan). Clot growth
was detected with red light scattering, and AMC fluorescence was excited
with UV LEDs. Fluorescence and scattered red light passing through the
macro lens were detected by a charge-coupled device system (Apogee
Imaging Systems, Roseville, CA). Images under red and blue light were
acquired once per minute. Data analysis is described in detail in the Sup-
porting Material.Blood collection and plasma preparation
Before the procedure, all volunteers provided written informed consent.
Experiments were performed with approval from the Ethical Committees
of the National Research Center for Hematology and Center for Theoretical
Problems of Physicochemical Pharmacology. Normal plasma pools (3–7
plasma samples) were obtained from freshly drawn human blood from
healthy volunteers. Blood was collected into 3.8% sodium citrate
(pH 5.5) at a 9:1 volume ratio and centrifuged at 1600  g for 15 min.
The supernatant was additionally centrifuged for 5 min at 10,000  g to
obtain platelet-free plasma, which was frozen and kept at 70C. Before
each experiment, plasma samples were thawed in a water bath. For pH
stabilization at 7.2–7.4, plasma was incubated with 10% lactic acid for
1 h at 37C (9). Commercially available coagulation factor-deficient plasma
samples were similarly treated after thawing.Spatial clot growth experiments in platelet-free
plasma
Plasma was supplemented with corn trypsin inhibitor (0.2 mg/ml), Z-Gly-
Gly-Arg-AMC (800 mM), 10 mM lipid vesicles (phosphatidylserine/phos-
phatidylcholine, at a 20:80 molar ratio), and thrombomodulin at the
indicated concentrations. Samples were incubated for 10 min at 37C and
then supplemented with CaCl2 (20 mM), immediately followed by clotting
initiation.Biophysical Journal 103(10) 2233–2240Spatial clot growth experiments in platelet-rich
plasma
Blood was collected directly into citrate with corn trypsin inhibitor (final
concentration 0.2 mg/ml) to minimize contact activation. Platelet-rich
plasma was obtained by centrifugation for 8 min at 100  g. The platelet
count was adjusted to 250,000 platelets/mL, and the pH level was stabilized
at 7.4 by the addition of 20 mMHepes. To prevent clot retraction, the glyco-
protein IIb/IIIa-inhibiting antibody fragment Monafram (25 mg/mL) was
used, and experiments were performed in 0.5% low melting point agarose.
Samples were prepared as described previously. After recalcification,
plasma was prewarmed to 42C for 2 min. Agarose solution was added,
and the mixture was incubated in the experimental cuvette for 3 min to
form a gel. The experiment was started as described previously.Spatial clot growth experiments in defibrinated
plasma
Platelet-free plasma (prepared as described previously) was defibrinated by
incubation with 0.02 NIH thrombin units of ancistron (Tekhnologiya-Stand-
art, Barnaul, Russia) at 37C for 1 h, followed by fibrin clot removal. The
experiments were performed in an agarose gel, as described previously.RESULTS
Method description
To study spatial dynamics of blood coagulation, we devel-
oped a fluorogenic substrate-based videomicroscopy method
for time- and space-resolved imaging of thrombin activity
(Fig. 1 A). Clotting was initiated by a layer of immobilized
TF, a transmembrane glycoprotein that activates coagulation
on the damaged vascular wall surface. Clotting propagated
from the activation surface into the bulk of plasma. The
Wave Propagation of Thrombin Activity 2235fluorogenic thrombin-specific peptide substrate Z-Gly-Gly-
Arg-AMC was added to the plasma, so that its cleavage by
thrombin produced a fluorescent molecule of AMC
(Fig. 1 B). The growing fibrin clot was sequentially illumi-
nated by red or UV light to image light scattered by the fibrin
clot or spatiotemporal distribution of AMC fluorescence,
respectively (Fig. 1C). Fibrin concentration profileswere ob-
tained from the light scattering intensity (see Fig. 1 E), and
the AMC distribution (Fig. 1 D) was used to calculate
thrombin (Fig. 1 F). The central idea for our approach is
derived from the standard mass-balance equation for AMC,
which infers that if the rate laws of fluorophore production
and diffusion are known the experimentally measured
AMC distribution can then be used to reconstruct the source
term in this equation, i.e., thrombin activity as a function of
space and time. The basic reaction-diffusion equation
v½AMC
vt
¼ DAMC , v
2½AMC
vx2
þ kcat , ½S , ½IIa
KM þ ½S ; (1)
was transformed
½IIa ¼ KM þ ½S
kcat , ½S ,

v½AMC
vt
 DAMC , v
2½AMC
vx2

: (2)
Thus, the time- and space-resolved thrombin activity distri-
bution was calculated by numerically solving an inverse
reaction-diffusion problem (10) (see the Supporting Mate-
rial for the detailed algorithm description) modified to
account for AMC binding in plasma and fluorescence distor-
tion caused by the fibrin clot (Fig. S1 and Fig. S2 in the Sup-
porting Material).Thrombin propagation determines formation
of fibrin clot
Fibrin clot initiated by a TF-covered surface steadily prop-
agated in normal plasma at a constant spatial velocity of
~20–50 mm/min (Fig. 1 E) and was apparently driven by
an impulse-like wave of thrombin with a constant thrombin
peak amplitude of 50–100 nM (Fig. 1 F and Movie S1). To
investigate if clot formation regulates thrombin generation
via reversible inhibition of thrombin by fibrin, or via
protection of thrombin from inhibition by antithrombin
III, or via acceleration of factor XI activation, we depleted
fibrinogen using a fibrin-cleaving protease from snake
venom. In defibrinated plasma, thrombin spatial propaga-
tion was qualitatively similar (Fig. S3), indicating that
thrombin wave propagation is an independent phenomenon
not determined by formation of polymerized fibrin clot.Thrombin wave reveals properties of a traveling
wave in an excitable medium
An important aspect of traveling waves in active media is
the formation of identical waves after a relatively broadrange of stimuli because the traveling wave is regulated
by properties of active media and not by the history of its
activation. To investigate the effect of initial stimulus on
the properties of propagating thrombin wave, we prepared
activators of different potency by changing the density of
immobilized TF. The waves obtained by using 90 pmol/
m2 (Fig. 2 A) or 4 pmol/m2 (Fig. 2 B) of TF were very
similar (Fig. 2, C and D). It should be noted that the lowest
TF density corresponds to just a few TF molecules per
squared micron; this is, however, only by an order of magni-
tude lower than TF density on highly active fibroblasts (6),
and comparable to macrophages and endothelial cells (11).
Thus, thrombin activity waves travel continuously at
a constant spatial velocity, have a constant shape and nonde-
caying amplitude, and are independent of the initial condi-
tions once the activation signal exceeds the threshold:
these are necessary and sufficient traits of a traveling
wave in an excitable medium (12).
In contrast, this wave was sensitive to the properties of the
medium. It did not propagate steadily in platelet-free plasma
that was not supplemented with phospholipids (Fig. 2 E;
Fig. S4) or platelets (Fig. 2 F), able to accelerate
membrane-dependent reactions comprising the positive
feedback loops of blood coagulation. Thrombin peak ampli-
tude was particularly sensitive to phospholipid concentra-
tion, whereas the spatial propagation velocity of this wave
was not.Positive feedback loops are essential for wave
propagation
Excitation wave formation requires the existence of positive
feedback loops that support self-sustained propagation inde-
pendently of the activator. Blood coagulation possesses at
least one such feedback: factor XI activation with thrombin
(13) as shown in Fig. 3 A. Other positive feedbacks, such as
factor V, VII, and VIII activation, do not lead to formation of
independently active enzymes and are therefore incapable
of sustaining indefinite propagation in space. Severe factor
XI deficiency, or hemophilia type C, is a rare bleeding
disease. The mechanism of this bleeding is controversial,
because of the apparently complementary role of factor XI
in the coagulation cascade: it is unclear why humans require
the minute quantities of factor IXa produced by thrombin-
activated factor XIa, if there is an abundance of factor IXa
produced by VIIa-TF (6). One possible explanation in
view of the findings of this study could be that factor XI acti-
vation by thrombin forms an excitation wave that propagates
clotting far from the activation site than could be necessary
for large wound sealing.
To test this hypothesis experimentally, we performed
studies with factor XI-deficient plasma from a hemophilia
C patient (Fig. 3 B). A traveling wave did not form in this
plasma, but was generated when a normal concentration
of factor XI was added. Factor VIII deficiency, a severeBiophysical Journal 103(10) 2233–2240
FIGURE 2 Propagating thrombin wave
possesses characteristic properties of a traveling
wave in an excitable medium. (A and B) Spatio-
temporal thrombin distribution after clotting stim-
ulation in normal plasma supplemented with
10 mM phospholipids with different TF densities.
(C and D) Thrombin spatial velocity (A) and
peak amplitude (B) for these two experiments. At
the p ¼ 0.05 level (n ¼ 8 experiments with plasma
from different donors), the thrombin peak height
and velocity are not different for these two activa-
tion levels. (E and F) Typical thrombin profiles in
platelet-free plasma without phospholipid supple-
mentation (E) or in platelet-rich plasma (F). A
typical experiment (out of n ¼ 3) is shown. Stimu-
lation is with 4 pmol TF/m2.
2236 Dashkevich et al.bleeding disorder known as hemophilia type A, also pre-
vented thrombin wave formation (Fig. S5). Interestingly,
computer simulation analysis suggested that factor XI defi-
ciency is in a way more fundamental for the traveling wave
phenomenon far from the activator, because factor XIa is an
enzyme that is indispensable for autocatalytic thrombin
production far from the activator, whereas factor VIIIa is
only a cofactor (Figs. S6–S8). Although this might seem
paradoxical, as factor VIII is well known to be much more
important clinically, however this actually agrees with the
previous observation that factor VIII is important for clot
formation at smaller distances (1–2 mm) from the activator,
whereas factor XI becomes essential and indispensable at
later stages for larger clots (6), i.e., exactly when the trav-
eling wave is observed.Protein C pathway is responsible for thrombin
wave limitation in space
Our previous studies suggested that different modules in
the coagulation network are responsible for specific tasks
such as activation threshold formation, spatial propagation,
and termination of this propagation (14). In particular,
stimulation of the anticoagulant protein C pathway withBiophysical Journal 103(10) 2233–2240naturally occurring allosteric regulator of thrombin throm-
bomodulin (Fig. 3 A) was previously found to regulate clot
size (6). To study the possible effect of this pathway on the
traveling wave of thrombin, we performed experiments
with different thrombomodulin concentrations. Stimulation
of the anticoagulant protein C pathway led to nonstationary
patterns of wave formation followed by its deceleration and
annihilation (Fig. 4, A and B, and Movie S2). Computer
simulation is shown in Fig. S9. Clot propagation was initi-
ated normally and then abruptly stopped at different
distances from the activator. Several interesting and
unusual patterns of traveling wave propagation were
observed: at low thrombomodulin concentration, the initial
velocity was steady, followed by deceleration and thrombin
peak decrease, whereas at higher concentrations, thrombin
peak ran for some distance, and then decelerated and
stopped. Existence of various modes of wave propagation
and pattern formation is another known feature of active
media.
Normally TM is localized at the undamaged vessel walls.
To compare effects of soluble and immobilized TM we per-
formed additional computer simulation (Fig. S10) showing
that TM immobilized far from a TF-coated surface can
stop thrombin propagation as well.
FIGURE 3 Traveling wave of thrombin activity is determined by positive feedbacks in the coagulation network. (A) The coagulation network contains posi-
tive feedbacks (filledwith gray) that can support self-sustained propagation of the thrombin impulse. FactorXI, located at the top of the cascade, can be activated
by thrombin in a feedback that is typical for excitable media. (B) Fibrin clot (upper row) and thrombin formation (lower) in factor XI-deficient plasma supple-
mented with 5 mM phospholipids and different concentrations of factor XI; a typical experiment is shown (out of n ¼ 2). See also Figs. S5–S8.
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In summary, we observed that the contact of plasma with TF
results in TF-dependent thrombin generation in a 0.5- to
1-mm area near the TF-expressing surface. Within 10–
40 min, a thrombin wave was formed that moved away
from the area of activation at a rate and height that were
independent of the initial activating signal. Our main finding
is that blood can function as an excitable medium to support
thrombin wave propagation. This phenomenon is easy to
observe and reproduce mathematically and experimentally,
and may serve as an example and research tool for syner-
getics research.
How are the observed time and space scales related to the
(patho)physiological ones? The traveling wave of our study
requires ~1–1.5 mm to form, and it has a wavefront width of
0.2–0.3 mm. Such a wave can be imagined in a large wound
(Fig. 4 C), where it can efficiently spread fibrin formation.
This is in line with the usual clinical presentation of hemo-
philia C in large-scale wounds or surgery (15). In case ofhemophilia C, absence of the travelling wave of thrombin,
that can form a large-scale fibrin clot, could lead to severe
bleeding. Therefore, the patients do not have problems
with small wounds as it does not require rapid long-distance
thrombin propagation. Thrombomodulin present in abun-
dance in the normal endothelium would prevent this wave
from entering healthy vessels. Thus, the fact that blood
can function as an excitable medium to support thrombin
wave propagation not only provides a new, to our knowl-
edge, biological nonlinear dynamic system, but also appears
to be important for fulfillment of the physiological function
of the coagulation system.
We proposed a possible mode for the thrombin traveling
wave in vivo, which should help provide a novel, to our
knowledge, understanding of the role of thrombin-induced
factor XI activation in blood clotting (Fig. 4 C). On the basis
of our experiments, computer simulations, and the clinical
presentation of hemophilia C (i.e., uncontrollable bleeding,
usually in cases of large-scale wounds or surgery (15)), weBiophysical Journal 103(10) 2233–2240
FIGURE 4 Traveling wave propagation is stopped by thrombomodulin: possible implications for confining a hemostatic plug to the wound. (A) Spatio-
temporally resolved distribution of thrombin in normal plasma supplemented with different concentrations of thrombomodulin, as indicated in the panels.
Plasma is supplemented with 10 mM phospholipids. Activation is with 4 pmol TF/m2. A typical experiment (out of n¼ 5) is shown. (B) Clot size (main plot),
spatial velocity (left inset), and thrombin peak amplitude (right inset) as functions of time for different thrombomodulin concentrations. (C) Hypothetical
function of the traveling wave of thrombin in vivo. In a sufficiently large wound, it is necessary to turn all of the blood into a gel, and to spread the clot
from the TF-containing injury site into the bulk of the blood. This task is possible, because thrombin propagation can be self-sustained due to factor XI
feedback activation, which explains the bleeding upon large injuries in hemophilia C. Abundant thrombomodulin in the healthy blood vessel endothelium
prevents the traveling wave from entering the healthy vasculature.
2238 Dashkevich et al.speculate that the excitation wave of thrombin, formed as
a result of the positive feedback loop of factor XI activation,
propagates the clotting process across large wounds and far
from the TF-expressing surface, resulting in efficient wound
sealing. However, when thrombomodulin is abundant (e.g.,
in normal endothelium), the wave is prevented from
entering healthy vessels.
Factor XI activation with thrombin reportedly can
produce additional thrombin to protect the fibrin clot from
fibrinolysis (16) and to provide sustained thrombin genera-
tion (17). However, to achieve these effects, it would be
evolutionarily simpler to induce more rapid thrombin acti-
vation, instead of introducing a new positive feedback
loop. Rapid and steady spatial signal propagation across
significant distances in a heterogeneous system cannot be
resolved in a way other than through creation of an excitable
medium with traveling waves, as evidenced by neural
impulse propagation. In this study, we experimentally
confirm this role of factor XI, which we previously proposed
on the basis of computer simulation results (1,2).
Although steady propagation of a traveling wave can be
beneficial, it also can be a potentially dangerous dynamic
factor. Factor XI plays a significant role in thrombosis
(18), which is caused by intravascular formation of
platelet-fibrin clots that obstruct blood flow through bloodBiophysical Journal 103(10) 2233–2240vessels. Thrombosis is a ubiquitous complication and cause
of numerous diseases and conditions, such as atheroscle-
rosis, trauma, stroke, infarction, cancer, and sepsis. Up to
70% of sudden cardiac deaths are due to thrombosis (19),
and sudden cardiac deaths kill ~400,000 people annually
in the United States alone (20). Thrombin-dependent factor
XI activation feedback may also explain why factor XI is
a potential target of antithrombotic drugs (21).SUPPORTING MATERIAL
Data analysis, computer simulations, supporting data, references (22)–(77),
and two movies are available at http://www.biophysj.org/biophysj/
supplemental/S0006-3495(12)01114-9.
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